TerminatedNCT04049266
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
PHASE2 · PHASE3 · 559 planned enrolment
- Countries listed
- 7
- Registry update
- July 18, 2024
